{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:57:18Z","timestamp":1781643438951,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473467"],"award-info":[{"award-number":["82473467"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Proteins represent the dynamic downstream products of genes, and have the potential to substantially increase understanding of the complexities of cancer biology. Undifferentiated pleomorphic sarcoma (UPS) is a rare disease, the proteomic landscape of which has not been fully investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed isobaric TMT-based proteomic analysis for 80 UPS tumor and 28 corresponding adjacent non-tumor muscle tissues. The underlying molecular subtypes, therapeutic targets, local recurrence, and lung metastasis were uncovered. The integration of previous single-cell RNA sequencing data with proteomics was further employed to characterize the specific cell type linked to lung metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our analyses revealed a catalog of proteins that were dysregulated in UPS. The UPS cohort was stratified into three molecular subtypes S-I, S-II, and S-III. S-I was characterized by the high expression of spliceosome-related proteins and protumor cytokines, and was associated with the lowest overall rate of survival. S-II was characterized with the highest ImmuneScore. S-III with the highest StromaScore had the best outcomes. Protein-based disease classification was better than the recommended AJCC staging system for UPS. PRMT6 protein was overexpressed, and associated with adverse outcomes. PRMT6 inhibitor significantly inhibited tumor growth in two patient-derived xenograft models. Analysis of local recurrence-associated proteins showed that PAWR was negatively associated with UPS recurrence. Additionally, CD163 was a negative predictive marker for lung metastasis. Combined with scRNA-seq data, CD163\u2009+\u2009macrophages represented phagocytosis phenotype with high expression of the signature markers (CD163, MRC1, MERTK, and C1QB). Furthermore, CD163\u2009+\u2009macrophages were enriched in the endocytosis, phagocytosis, and lysosome compared with CD163- macrophages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study highlights the utility of proteomics for characterizing UPS, providing a framework for understanding the biological basis of its clinical features and paving the way for a new era of proteomics-driven precision medicine in sarcoma research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13073-026-01626-w","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T11:02:28Z","timestamp":1774004548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proteomic landscape analysis of undifferentiated pleomorphic sarcoma"],"prefix":"10.1186","volume":"18","author":[{"given":"Biqiang","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingnan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangjun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"issue":"4","key":"1626_CR1","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1158\/1078-0432.CCR-14-2399","volume":"21","author":"J Hofvander","year":"2015","unstructured":"Hofvander J, et al. Recurrent PRDM10 gene fusions in undifferentiated pleomorphic sarcoma. Clin Cancer Res. 2015;21(4):864\u20139.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"1626_CR2","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1038\/modpathol.2013.174","volume":"27","author":"JR Goldblum","year":"2014","unstructured":"Goldblum JR. An approach to pleomorphic sarcomas: can we subclassify, and does it matter? Mod Pathol. 2014;27(Suppl 1):S39\u201346.","journal-title":"Mod Pathol"},{"issue":"1","key":"1626_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/ijc.31039","volume":"142","author":"J Lewin","year":"2018","unstructured":"Lewin J, et al. Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma. Int J Cancer. 2018;142(1):57\u201365.","journal-title":"Int J Cancer"},{"issue":"2","key":"1626_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jamcollsurg.2009.10.007","volume":"210","author":"RJ Canter","year":"2010","unstructured":"Canter RJ, et al. Interaction of histologic subtype and histologic grade in predicting survival for soft-tissue sarcomas. J Am Coll Surg. 2010;210(2):191\u20138. e2.","journal-title":"J Am Coll Surg"},{"issue":"4","key":"1626_CR5","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","volume":"171","author":"Cancer Genome Atlas Research Network","year":"2017","unstructured":"Cancer Genome Atlas Research Network. Electronic address, e.d.s.c. and N. Cancer Genome Atlas Research, Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell. 2017;171(4):950\u2013e96528.","journal-title":"Cell"},{"issue":"3","key":"1626_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ccell.2019.02.002","volume":"35","author":"CD Steele","year":"2019","unstructured":"Steele CD, et al. Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways. Cancer Cell. 2019;35(3):441\u2013e4568.","journal-title":"Cancer Cell"},{"issue":"18","key":"1626_CR7","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/s41388-024-03001-8","volume":"43","author":"Y Lu","year":"2024","unstructured":"Lu Y, et al. Single-cell landscape of undifferentiated pleomorphic sarcoma. Oncogene. 2024;43(18):1353\u201368.","journal-title":"Oncogene"},{"issue":"1","key":"1626_CR8","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1038\/s41467-021-25202-5","volume":"12","author":"W Liu","year":"2021","unstructured":"Liu W, et al. Large-scale and high-resolution mass spectrometry-based proteomics profiling defines molecular subtypes of esophageal cancer for therapeutic targeting. Nat Commun. 2021;12(1):4961.","journal-title":"Nat Commun"},{"issue":"19","key":"1626_CR9","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1016\/j.cell.2021.08.023","volume":"184","author":"L Cao","year":"2021","unstructured":"Cao L, et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell. 2021;184(19):5031\u2013e505226.","journal-title":"Cell"},{"issue":"7747","key":"1626_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41586-019-0987-8","volume":"567","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature. 2019;567(7747):257\u201361.","journal-title":"Nature"},{"issue":"4","key":"1626_CR11","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.cell.2019.03.030","volume":"177","author":"S Vasaikar","year":"2019","unstructured":"Vasaikar S, et al. Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities. Cell. 2019;177(4):1035\u2013e104919.","journal-title":"Cell"},{"issue":"4","key":"1626_CR12","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.celrep.2015.03.050","volume":"11","author":"RT Lawrence","year":"2015","unstructured":"Lawrence RT, et al. The proteomic landscape of triple-negative breast cancer. Cell Rep. 2015;11(4):630\u201344.","journal-title":"Cell Rep"},{"issue":"1","key":"1626_CR13","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1038\/s41467-023-39486-2","volume":"14","author":"J Burns","year":"2023","unstructured":"Burns J, et al. The proteomic landscape of soft tissue sarcomas. Nat Commun. 2023;14(1):3834.","journal-title":"Nat Commun"},{"issue":"1","key":"1626_CR14","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41467-024-45306-y","volume":"15","author":"S Tang","year":"2024","unstructured":"Tang S, et al. Proteomic characterization identifies clinically relevant subgroups of soft tissue sarcoma. Nat Commun. 2024;15(1):1381.","journal-title":"Nat Commun"},{"issue":"6","key":"1626_CR15","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev A, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021;39(6):845\u2013e8657.","journal-title":"Cancer Cell"},{"issue":"1","key":"1626_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220.","journal-title":"Genome Biol"},{"issue":"10","key":"1626_CR17","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41419-023-06148-6","volume":"14","author":"Q Chen","year":"2023","unstructured":"Chen Q, et al. PRMT6 methylation of STAT3 regulates tumor metastasis in breast cancer. Cell Death Dis. 2023;14(10):655.","journal-title":"Cell Death Dis"},{"issue":"9","key":"1626_CR18","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1158\/0008-5472.CAN-13-2133","volume":"74","author":"CA Walsh","year":"2014","unstructured":"Walsh CA, et al. Global gene repression by the steroid receptor coactivator SRC-1 promotes oncogenesis. Cancer Res. 2014;74(9):2533\u201344.","journal-title":"Cancer Res"},{"issue":"6","key":"1626_CR19","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.molcel.2021.01.015","volume":"81","author":"T Huang","year":"2021","unstructured":"Huang T, et al. PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. Mol Cell. 2021;81(6):1276\u2013e12919.","journal-title":"Mol Cell"},{"issue":"1","key":"1626_CR20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41467-020-20361-3","volume":"12","author":"MM Gladka","year":"2021","unstructured":"Gladka MM, et al. Cardiomyocytes stimulate angiogenesis after ischemic injury in a ZEB2-dependent manner. Nat Commun. 2021;12(1):84.","journal-title":"Nat Commun"},{"issue":"1","key":"1626_CR21","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1038\/s41467-020-17212-6","volume":"11","author":"N Alzahofi","year":"2020","unstructured":"Alzahofi N, et al. Rab27a co-ordinates actin-dependent transport by controlling organelle-associated motors and track assembly proteins. Nat Commun. 2020;11(1):3495.","journal-title":"Nat Commun"},{"issue":"1","key":"1626_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12943-024-02019-6","volume":"23","author":"Y Li","year":"2024","unstructured":"Li Y, et al. CircTRIM1 encodes TRIM1-269aa to promote chemoresistance and metastasis of TNBC via enhancing CaM-dependent MARCKS translocation and PI3K\/AKT\/mTOR activation. Mol Cancer. 2024;23(1):102.","journal-title":"Mol Cancer"},{"issue":"14","key":"1626_CR23","doi-asserted-by":"publisher","first-page":"e2202737","DOI":"10.1002\/advs.202202737","volume":"10","author":"T Yang","year":"2023","unstructured":"Yang T, et al. The PRMT6\/PARP1\/CRL4B Complex Regulates the Circadian Clock and Promotes Breast Tumorigenesis. Adv Sci (Weinh). 2023;10(14):e2202737.","journal-title":"Adv Sci (Weinh)"},{"key":"1626_CR24","doi-asserted-by":"publisher","first-page":"216442","DOI":"10.1016\/j.canlet.2023.216442","volume":"578","author":"R Kong","year":"2023","unstructured":"Kong R, et al. Hypoxia-induced circ-CDYL-EEF1A2 transcriptional complex drives lung metastasis of cancer stem cells from hepatocellular carcinoma. Cancer Lett. 2023;578:216442.","journal-title":"Cancer Lett"},{"issue":"1","key":"1626_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ccr.2013.05.007","volume":"24","author":"JV Alvarez","year":"2013","unstructured":"Alvarez JV, et al. Par-4 downregulation promotes breast cancer recurrence by preventing multinucleation following targeted therapy. Cancer Cell. 2013;24(1):30\u201344.","journal-title":"Cancer Cell"},{"issue":"1","key":"1626_CR26","doi-asserted-by":"publisher","first-page":"1747340","DOI":"10.1080\/2162402X.2020.1747340","volume":"9","author":"AR Dancsok","year":"2020","unstructured":"Dancsok AR, et al. Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. Oncoimmunology. 2020;9(1):1747340.","journal-title":"Oncoimmunology"},{"issue":"3","key":"1626_CR27","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","volume":"184","author":"S Cheng","year":"2021","unstructured":"Cheng S, et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 2021;184(3):792\u2013e80923.","journal-title":"Cell"},{"key":"1626_CR28","doi-asserted-by":"crossref","unstructured":"Li J, et al. LincNEAT1 encoded-NEAT1-31 promotes phagocytosis by directly activating the Aurora-A-PI3K-AKT Pathway. Adv Sci (Weinh). 2025;12(30):e2413473.","DOI":"10.1002\/advs.202413473"},{"issue":"7655","key":"1626_CR29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545(7655):495\u20139.","journal-title":"Nature"},{"issue":"2","key":"1626_CR30","doi-asserted-by":"publisher","first-page":"108993","DOI":"10.1016\/j.celrep.2021.108993","volume":"35","author":"C Tacconi","year":"2021","unstructured":"Tacconi C, et al. CD169(+) lymph node macrophages have protective functions in mouse breast cancer metastasis. Cell Rep. 2021;35(2):108993.","journal-title":"Cell Rep"},{"issue":"5","key":"1626_CR31","doi-asserted-by":"publisher","first-page":"e202551804","DOI":"10.1002\/eji.202551804","volume":"55","author":"E Lebegge","year":"2025","unstructured":"Lebegge E, et al. VSIG4-Expressing Macrophages Contribute to Antiparasitic and Antimetastatic Responses in the Peritoneal Cavity. Eur J Immunol. 2025;55(5):e202551804.","journal-title":"Eur J Immunol"},{"issue":"4","key":"1626_CR32","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/jimmun\/vkae061","volume":"214","author":"F Rago","year":"2025","unstructured":"Rago F, et al. CD209d\/e are required for macrophage-mediated phagocytosis and activation during methicillin-resistant Staphylococcus aureus pulmonary host defense. J Immunol. 2025;214(4):703\u201313.","journal-title":"J Immunol"},{"issue":"7","key":"1626_CR33","doi-asserted-by":"publisher","first-page":"815","DOI":"10.6004\/jnccn.2022.0035","volume":"20","author":"M von Mehren","year":"2022","unstructured":"von Mehren M, et al. Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(7):815\u201333.","journal-title":"J Natl Compr Canc Netw"},{"key":"1626_CR34","doi-asserted-by":"publisher","first-page":"1591644","DOI":"10.3389\/fmolb.2025.1591644","volume":"12","author":"Y Wei","year":"2025","unstructured":"Wei Y, et al. Clinicopathologic and proteomic characteristics of low-grade undifferentiated spindle cell sarcoma. Front Mol Biosci. 2025;12:1591644.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"1626_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.molcel.2006.02.013","volume":"22","author":"N El-Andaloussi","year":"2006","unstructured":"El-Andaloussi N, et al. Arginine methylation regulates DNA polymerase beta. Mol Cell. 2006;22(1):51\u201362.","journal-title":"Mol Cell"},{"issue":"3","key":"1626_CR36","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1053\/j.gastro.2019.05.057","volume":"157","author":"Y Luo","year":"2019","unstructured":"Luo Y, et al. Intestinal PPARalpha Protects Against Colon Carcinogenesis via Regulation of Methyltransferases DNMT1 and PRMT6. Gastroenterology. 2019;157(3):744\u2013e7594.","journal-title":"Gastroenterology"},{"issue":"11","key":"1626_CR37","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493\u2013501.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1626_CR38","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s43018-024-00743-y","volume":"5","author":"A Subramanian","year":"2024","unstructured":"Subramanian A, et al. Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy. Nat Cancer. 2024;5(4):642\u201358.","journal-title":"Nat Cancer"},{"key":"1626_CR39","doi-asserted-by":"crossref","unstructured":"Vanni S, et al. Unveiling the genomic basis of chemosensitivity in sarcomas of the extremities: an integrated approach for an unmet clinical need. Int J Mol Sci. 2023;24(8):6926.","DOI":"10.3390\/ijms24086926"},{"key":"1626_CR40","doi-asserted-by":"crossref","unstructured":"De Vita A, et al. Primary culture of undifferentiated pleomorphic sarcoma: molecular characterization and response to anticancer agents. Int J Mol Sci. 2017;18(12):2662.","DOI":"10.3390\/ijms18122662"},{"issue":"1","key":"1626_CR41","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s42003-024-06430-z","volume":"7","author":"K Subburayan","year":"2024","unstructured":"Subburayan K, et al. Tumor suppressor Par-4 activates autophagy-dependent ferroptosis. Commun Biol. 2024;7(1):732.","journal-title":"Commun Biol"},{"issue":"1","key":"1626_CR42","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1186\/s12935-021-02354-4","volume":"21","author":"J Zhao","year":"2021","unstructured":"Zhao J, et al. PAR1 and PAR4 exert opposite effects on tumor growth and metastasis of esophageal squamous cell carcinoma via STAT3 and NF-kappaB signaling pathways. Cancer Cell Int. 2021;21(1):637.","journal-title":"Cancer Cell Int"},{"key":"1626_CR43","doi-asserted-by":"crossref","unstructured":"Zajac AE, Czarnecka AM, Rutkowski P. The role of macrophages in sarcoma tumor microenvironment and treatment. Cancers (Basel). 2023;15(21):5294.","DOI":"10.3390\/cancers15215294"},{"key":"1626_CR44","doi-asserted-by":"publisher","first-page":"1008484","DOI":"10.3389\/fonc.2022.1008484","volume":"12","author":"R Lazcano","year":"2022","unstructured":"Lazcano R, et al. The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol. 2022;12:1008484.","journal-title":"Front Oncol"},{"issue":"1","key":"1626_CR45","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","volume":"10","author":"J Xu","year":"2025","unstructured":"Xu J, et al. Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments. Signal Transduct Target Ther. 2025;10(1):268.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"1626_CR46","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-19-1824","volume":"26","author":"EZ Keung","year":"2020","unstructured":"Keung EZ, et al. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. Clin Cancer Res. 2020;26(6):1258\u201366.","journal-title":"Clin Cancer Res"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-026-01626-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01626-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01626-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:33:48Z","timestamp":1781642028000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13073-026-01626-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1626"],"URL":"https:\/\/doi.org\/10.1186\/s13073-026-01626-w","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tissue samples were collected at Fudan University Shanghai Cancer Center in accordance with the protocols approved by the Clinical Research Ethics Committee of the Fudan University Shanghai Cancer Center (Approval Number: 050432-4-2108). Animal experiments were approved by the Institutional Animal Care and Use Committee of Fudan University Shanghai Cancer Center (Protocol Number: FUSCC-IACUC-2022188). This study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}